{"id":32487,"date":"2025-04-27T16:32:44","date_gmt":"2025-04-27T08:32:44","guid":{"rendered":"https:\/\/flcube.com\/?p=32487"},"modified":"2025-04-27T16:32:45","modified_gmt":"2025-04-27T08:32:45","slug":"johnson-johnsons-tremfya-approved-by-ec-for-ulcerative-colitis-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32487","title":{"rendered":"Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment"},"content":{"rendered":"\n

US giant Johnson & Johnson (J&J; NYSE: JNJ<\/a>) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The EC\u2019s approval is supported by positive results from the QUASAR program, which includes Phase IIb induction dose-ranging and Phase III induction and maintenance studies. In the QUASAR maintenance study, 45% of patients receiving guselkumab 100mg subcutaneous (SC) maintenance every eight weeks (q8w) and 50% of patients receiving guselkumab 200mg SC every four weeks (q4w) achieved clinical remission at Week 44, compared to 19% of placebo-treated patients (p<0.001). The safety profile was consistent with previously known data.<\/p>\n\n\n\n

Drug Profile and Previous Approvals<\/strong>
Guselkumab is the first fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64. It was first approved in the European Union (EU) in November 2017 for the first-line treatment of moderate-to-severe plaque psoriasis. Subsequently, it secured approval to treat active psoriatic arthritis (PsA) in adult patients who had an inadequate response or were intolerant to prior disease-modifying anti-rheumatic drug therapy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval…<\/p>\n","protected":false},"author":1,"featured_media":32488,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[150,149,858,15],"class_list":["post-32487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-product-approvals"],"yoast_head":"\nJohnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment\" \/>\n<meta property=\"og:description\" content=\"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-27T08:32:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-27T08:32:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment\",\"datePublished\":\"2025-04-27T08:32:44+00:00\",\"dateModified\":\"2025-04-27T08:32:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2703.webp\",\"keywords\":[\"J&J\",\"Johnson & Johnson\",\"NYSE: JNJ\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32487#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32487\",\"name\":\"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2703.webp\",\"datePublished\":\"2025-04-27T08:32:44+00:00\",\"dateModified\":\"2025-04-27T08:32:45+00:00\",\"description\":\"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32487\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment - Insight, China's Pharmaceutical Industry","description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32487","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment","og_description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.","og_url":"https:\/\/flcube.com\/?p=32487","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-27T08:32:44+00:00","article_modified_time":"2025-04-27T08:32:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment","datePublished":"2025-04-27T08:32:44+00:00","dateModified":"2025-04-27T08:32:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32487"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","keywords":["J&J","Johnson & Johnson","NYSE: JNJ","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32487#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32487","url":"https:\/\/flcube.com\/?p=32487","name":"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32487#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","datePublished":"2025-04-27T08:32:44+00:00","dateModified":"2025-04-27T08:32:45+00:00","description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval from the European Commission (EC) for its Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC). The approval applies to patients who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32487"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32487#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","width":1080,"height":608,"caption":"Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32487"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32487\/revisions"}],"predecessor-version":[{"id":32489,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32487\/revisions\/32489"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32488"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}